Abstract:Background: Mitochondrial neurogastrointestinal encephalomyopathy (MNGIE) is a rare and progressive disease caused by mutations in the TYMP gene, which encodes the enzyme thymidine phosphorylase (TP). This results in a systemic accumulation of nucleosides and mitochondrial toxicity. AAV-based liver-directed gene therapy has shown efficacy in preclinical studies, but it has limitations such as a decline of transgene expression long-term. We propose that gene editing can circumvent some of these problems.Methods: We performed a preclinical study in the murine model of MNGIE to assess that the coordinated delivery of CRISPR/Cas9 and a TYMP cDNA caused the efficient integration of a TYMP transgene into introns of the Tymp and Alb loci in hepatocytes. CRISPR/Cas9 was delivered either as mRNA using nanoparticles or in AAV2/8 viral vectors; the latter were also used to package the TYMP cDNA. We assessed the efficient integration of the templates into the liver cells, and monitored the nucleoside levels in plasma to detect the biochemical correction.Findings: The best results were obtained using lipid nanoparticles. The consistent and stable nucleoside reduction observed correlated with the presence of TYMP mRNA and functional enzyme in the liver cells. In mice with an edited Alb locus, the transgene produced a hybrid Alb-hTP protein that was secreted, with high levels of TP activity in plasma.Interpretation: Liver-directed gene editing is a feasible approach to achieve the long-term biochemical correction of the disease, with several advantages over previous methods.Funding Information: This project was made possible with financial support from the Instituto de Salud Carlos III/FEDER (grant PI15/00172) and from MINECO/FEDER (grant RTI2018-094734-B-C22). The support of the Agència de Gestió d’Ajuts Universitaris i de Recerca (AGAUR) of the Generalitat de Catalunya, through SGR 2017 1559 grant, is also acknowledged.Declaration of Interests: S.H.Y.F. and Y.K.T. are employees of Acuitas Therapeutics, a company focused on the development of lipid nanoparticle delivery systems for nucleic-acid-based drugs. RM was the recipient of personal fees associated with advisory tasks and of financial support from Modis Therapeutics for research outside the submitted work. RM also holds a patent “Deoxynucleoside therapy for diseases caused by unbalanced nucleotide pools including mitochondrial DNA depletion syndromes” (PCT/US16/038110), with royalties paid to Modis Therapeutics.INCOMPLETEEthics Approval Statement: All animal procedures were performed in accordance with European recommendations and were approved by our institutional ethics committee (Comitè Ètic d’Experimentació Animal).

Template-independent genome editing and repairing correct frameshift disease in vivo

Template-independent genome editing in the <i>Pcdh15<SUP>av-3j</SUP></i> mouse, a model of human DFNB23 nonsyndromic deafness

Template-independent Genome Editing in the Pcdh15 Mouse, a Model of Human DFNB23 Nonsyndromic Deafness

Precise in vivo genome editing via single homology arm donor mediated intron-targeting gene integration for genetic disease correction

Treatment of autosomal recessive hearing loss via in vivo CRISPR/Cas9-mediated optimized homology-directed repair in mice

Harnessing accurate non-homologous end joining for efficient precise deletion in CRISPR/Cas9-mediated genome editing

Precise Detection of CRISPR-Cas9 Editing in Hair Cells in the Treatment of Autosomal Dominant Hearing Loss

Generation and Genetic Correction of USH2A c.2299delG Mutation in Patient-Derived Induced Pluripotent Stem Cells

Enhanced genome editing to ameliorate a genetic metabolic liver disease through co-delivery of adeno-associated virus receptor

Targeted genome editing restores auditory function in adult mice with progressive hearing loss caused by a human microRNA mutation

Treatment of autosomal dominant hearing loss by in vivo delivery of genome editing agents

Rescue of autosomal dominant hearing loss by in vivo delivery of mini dCas13X-derived RNA base editor

Using Transcriptomic Analysis to Assess Double-Strand Break Repair Activity: Towards Precise in vivo Genome Editing

Enhanced homology-directed repair for highly efficient gene editing in hematopoietic stem/progenitor cells

In Vivo Base Editing of Scn5a Rescues Type 3 Long QT Syndrome in Mice

Treatment of monogenic and digenic dominant genetic hearing loss by CRISPR-Cas9 ribonucleoprotein delivery in vivo

Dual guide RNA-mediated concurrent C&G-to-T&A and A&T-to-G&C conversions using CRISPR base editors

Correction of Three Prominent Mutations in Mouse and Human Models of Duchenne Muscular Dystrophy by Single-Cut Genome Editing

Preclinical Assessment of a Gene Editing Approach in a Mouse Model of MNGIE

Efficient Correction of a Hypertrophic Cardiomyopathy Mutation by ABEmax-NG

Precise Somatic Genome Editing for Treatment of Inborn Errors of Immunity.